Search

In this study, a rapid and straightforward approach based on magnetic ionic liquids (MIL) as extraction phases and dispersive liquid-liquid microextraction (DLLME) was developed to analyze the hormones estriol, 17-β-estradiol, 17-α-ethynylestradiol, and estrone in human urine samples. This is the first report of an application of manganese-based MILs compatible with HPLC to extract compounds of biological interest from urine samples. The hydrophobic MILs trihexyltetradecylphosphonium tetrachloromanganate (II) ([P 6,6,6,14 + ] 2 [MnCl 4 2- ]) and aliquat tetrachloromanganate (II) ([Aliquat + ] 2 [MnCl 4 2- ]) were employed and the optimized extraction conditions were comprised of 5 mg of MIL ([P 6,6,6,14 + ] 2 [MnCl 4 2- ]), 5 μL of methanol (MeOH) as disperser solvent, and an extraction time of 90 s at sample pH 6. The analytical parameters of merit were determined under optimized conditions and very satisfactory results were achieved, with LODs of 2 ng mL -1 for all analytes, determination coefficients (R 2 ) ranging from 0.9949 for 17-β-estradiol to 0.9998 for estrone. In addition, good results of method precision were achieved with the intraday (n = 3) varying from 4.7% for 17-β-estradiol to 19.5% for estriol (both at 5 ng mL -1 ) and interday precision (evaluated at 100 ng mL -1 ) ranging from 11.4% for estrone to 17.7% for 17-α-ethynylestradiol and analyte relative recovery evaluated in three real samples ranged from 67.5 to 115.6%. The proposed DLLME/MIL-based approach allowed for a reliable, environmentally friendly and high-throughput methodology with no need for a centrifugation step. Graphical abstract An overview of the rapid and straightforward extraction procedure using DLLME/MIL-based approach.

A novel sample preparation technique termed dynamic liquid-liquid-solid microextraction (DLLSME) was developed and on-line coupled to high performance liquid chromatography (HPLC) for direct extraction, desorption, and analysis of trace estrogens in complex samples. The DLLSME consists of the aqueous donor phase, the organic medium phase and the molecularly imprinted polymer filaments (MIPFs) as solid acceptor phase. The organic solvent with lesser density was directly added on top of the aqueous sample, and the dynamic extraction was performed by circulating the organic solvent through the MIPFs inserted into a PEEK tube which served as an extraction and desorption chamber. Afterwards, the extracted analytes on the MIPFs were on-line desorbed and then introduced into the HPLC for analysis. To evaluate the feasibility of the on-line system, a new DLLSME-HPLC method was developed for the analysis of five estrogens in aqueous samples by using 17β-estradiol MIPFs as the solid phase. Under the optimized conditions, the enrichment factors of 51-70, limits of detection of 0.08-0.25 μg/L and precision within 4.5-6.9% were achieved. Furthermore, the proposed method was applied to the analysis of real samples including urine, milk and skin toner, satisfactory recovery (81.9-99.8%) and reproducibility (4.1-7.9%) were obtained. Especially, 0.59 μg/L of 17β-estradiol was determined in female urine sample. The DLLSME offers an attractive alternative for direct analysis of trace analytes in aqueous samples and could potentially be extended to other adsorptive materials., (Copyright © 2012 Elsevier B.V. All rights reserved.)

Hospital effluent and connected waste water treatment plant (WWTP) influent and effluent were sampled daily to determine the levels and inter-day variations of three naturally occurring steroid estrogens: estrone, 17β-estradiol, estriol, and synthetic 17α-ethinylestradiol. After solid phase extraction, interferences were removed with a silica gel clean-up step and the samples analysed using gas chromatography with mass selective detection (GC-MSD). The determined inter-day concentrations in hospital effluent were between 8.6 to 31.3 ng L(-1) for estrone,

The metabolism and elimination of estradiol (E2) and ethynylestradiol (EE2) were examined in adult female rhesus monkeys treated with two different combinational oral contraceptive agents at 10x the human equivalent dose. Ethynerone/mestranol (20:1), anagestone/mestranol (10:1), or vehicle was administered by gavage over a 10-year period on a cycling schedule of 21 days of dosing followed by 7 days without. At the end of the 28-day cycle, six monkeys in each group were anesthetized and administered a 14C-E2/3H-EE2 dose iv. Serial blood samples collected before and up to 6 hr after dosing were analyzed for total radioactivity and the percentage of parent compound and each metabolite was determined by HPLC. Radioimmunoassay of the baseline samples revealed that the plasma concentration of endogenous E2 was lower in the ethynerone/mestranol-treated group as compared to the vehicle control group. The total radioactivity derived from 14C-E2 was more rapidly eliminated from the plasma of the ethynerone/mestranol group than the control group. In addition, the percentages of HPLC-resolved E2 and EE2 were less in the treated group while the percentages of estrone, estrone glucuronide, and EE2 3-sulfate were enhanced as compared to the control group. The anagestone/mestranol group exhibited the same trends as the ethynerone/mestranol group but the data were not generally statistically different from the control group. These data indicate that chronically administered progestin/estrogen oral contraceptive agents reduce endogenous plasma E2 concentrations at least in part by enhancing the biotransformation of E2 to rapidly eliminated metabolites.